BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26190263)

  • 1. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.
    Wong SH; Goode DL; Iwasaki M; Wei MC; Kuo HP; Zhu L; Schneidawind D; Duque-Afonso J; Weng Z; Cleary ML
    Cancer Cell; 2015 Aug; 28(2):198-209. PubMed ID: 26190263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
    J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.
    Izaguirre-Carbonell J; Christiansen L; Burns R; Schmitz J; Li C; Mokry RL; Bluemn T; Zheng Y; Shen J; Carlson KS; Rao S; Wang D; Zhu N
    Blood Adv; 2019 May; 3(9):1499-1511. PubMed ID: 31076406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
    Xhabija B; Kidder BL
    Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone demethylase lysine demethylase 5B in development and cancer.
    Han M; Xu W; Cheng P; Jin H; Wang X
    Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
    Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
    Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation.
    Kidder BL; Hu G; Zhao K
    Genome Biol; 2014 Feb; 15(2):R32. PubMed ID: 24495580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plzf drives MLL-fusion-mediated leukemogenesis specifically in long-term hematopoietic stem cells.
    Ono R; Masuya M; Nakajima H; Enomoto Y; Miyata E; Nakamura A; Ishii S; Suzuki K; Shibata-Minoshima F; Katayama N; Kitamura T; Nosaka T
    Blood; 2013 Aug; 122(7):1271-83. PubMed ID: 23838347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
    Cheung N; Fung TK; Zeisig BB; Holmes K; Rane JK; Mowen KA; Finn MG; Lenhard B; Chan LC; So CW
    Cancer Cell; 2016 Jan; 29(1):32-48. PubMed ID: 26766589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
    Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
    Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
    Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness.
    Grinat J; Heuberger J; Vidal RO; Goveas N; Kosel F; Berenguer-Llergo A; Kranz A; Wulf-Goldenberg A; Behrens D; Melcher B; Sauer S; Vieth M; Batlle E; Stewart AF; Birchmeier W
    Nat Commun; 2020 Dec; 11(1):6422. PubMed ID: 33349639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
    Godfrey L; Crump NT; O'Byrne S; Lau IJ; Rice S; Harman JR; Jackson T; Elliott N; Buck G; Connor C; Thorne R; Knapp DJHF; Heidenreich O; Vyas P; Menendez P; Inglott S; Ancliff P; Geng H; Roberts I; Roy A; Milne TA
    Leukemia; 2021 Jan; 35(1):90-106. PubMed ID: 32242051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
    Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
    Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.